Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 29Neoplasms 5Glioma 4Ovarian Neoplasms 3Neoplasm Metastasis 3Melanoma 3Glioblastoma 3Rhabdoid Tumor 2Neoplasms, Germ Cell and Embryonal 2Medulloblastoma 2Lymphoma 2Liposarcoma 2Fallopian Tube Neoplasms 2Diffuse Intrinsic Pontine Glioma 2Brain Neoplasms 2Astrocytoma 2Thymus Neoplasms 1Teratoma 1Solid Tumors Harboring a BRAF V600 Mutation 1Sarcoma, Synovial 1Sarcoma 1Recurrence 1Pyloric Stenosis, Hypertrophic 1Prostatic Neoplasms 1Pinealoma 1Osteitis Deformans 1Oligodendroglioma 1Non functioning pancreatic endocrine tumor 1Neurofibrosarcoma 1Neuroendocrine Tumors 1

Interventions

ribociclib 1Tamoxifen 1Letrozole 1Goserelin 1Fulvestrant 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer × ribociclib × Clear all
NCT02333370 2023-06-08

A Phase Ib Dose Escalation Study of the Combination of LEE011 With Letrozole and Dose Expansion of LEE011 With Hormonal Therapy for the Treatment of Pre-(With Goserelin) and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer

Novartis

Phase 1 Completed
88 enrolled
Breast

Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡